Therapeutics News and Research

RSS

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Echo Therapeutics proposes to file investor presentation with SEC

Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is filing an investor presentation with the U.S. Securities and Exchange Commission (SEC) that comments on, among other things, the pending proxy contest by a dissident stockholder group led by Platinum Management (NY) LLC.

30 May 2014

Perelman School wins $10M renewal to study oldest part of human immune system

The National Institute of Allergy and Infectious Diseases has awarded the Perelman School of Medicine at the University of Pennsylvania a five-year, $10 million renewal of a program project to study the oldest part of the human immune system called the complement system, or simply "complement."

30 May 2014

Blood gene expression profile identifies patients with elevated risk of cardiovascular death

A study of 338 patients with coronary artery disease has identified a gene expression profile associated with an elevated risk of cardiovascular death. Used with other indicators such as biochemical markers and family history, the profile - based on a simple blood test - may help identify patients who could benefit from personalized treatment and counseling designed to address risk factors.

30 May 2014

Researchers study why male babies generally have worse outcomes than females

Sexual inequality between boys and girls starts as early as in the mother's womb - but how and why this occurs could be a key to preventing higher rates of preterm birth, stillbirth and neonatal death among boys.

28 May 2014

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Researchers discover novel enzyme that promotes insulin secretion in type 2 diabetes animal model

A signal that promotes insulin secretion and reduces hyperglycemia in a type 2 diabetes animal model is enhanced by the inhibition of a novel enzyme discovered by CHUM Research Centre (CRCHUM) and University of Montreal researchers.

26 May 2014

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

PTC Therapeutics, Inc. today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.

23 May 2014

TUSM scientists receive $11.5M grant to develop innovative treatments for heart failure

Innovative treatments for heart failure are lacking, leaving the nearly six million Americans who suffer from the condition with little hope for a cure.

23 May 2014

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that Acceleron, Celgene and investigators in the sotatercept and ACE-536 phase 2 clinical trials will give three oral presentations of interim data from ongoing studies in beta-thalassemia and myelodysplastic syndromes as well as a poster presentation of nonclinical data in sickle cell disease at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy from June 12-15, 2014.

22 May 2014

Sanford-Burnham, Daiichi enter into comprehensive alliance to develop first-in-class therapeutics

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.

22 May 2014

VTT scientists discover unknown Cent-1 molecule that kills cancer cells

A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells.

22 May 2014

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.

21 May 2014

New cancer drug candidates can be identified faster by using computer-assisted screening

21 May 2014

Substance from pine bark is a potential source for treating melanoma

A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.

21 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced the presentation by Juventas Therapeutics of their positive four-month results for their STOP-HF Trial.

20 May 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Therapeutics News and Research

Agena Bioscience expands ultrasensitive somatic mutation detection technology

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Echo Therapeutics proposes to file investor presentation with SEC

Perelman School wins $10M renewal to study oldest part of human immune system

Blood gene expression profile identifies patients with elevated risk of cardiovascular death

Researchers study why male babies generally have worse outcomes than females

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Researchers discover novel enzyme that promotes insulin secretion in type 2 diabetes animal model

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

TUSM scientists receive $11.5M grant to develop innovative treatments for heart failure

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Sanford-Burnham, Daiichi enter into comprehensive alliance to develop first-in-class therapeutics

VTT scientists discover unknown Cent-1 molecule that kills cancer cells

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

New cancer drug candidates can be identified faster by using computer-assisted screening

Substance from pine bark is a potential source for treating melanoma

Existing pharmaceutical drugs may offer effective therapies against MERS

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News